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Abstract
Objectives: Patients with type 2 diabetes (T2DM) are at increased fracture risk. Resveratrol has shown beneficial effects
on bone health in few studies. The aim of this trial was to investigate the effects of resveratrol on bone mineral density
(BMD) and on calcium metabolism biomarkers in T2DM patients.
Methods: In this double-blind randomized placebo-controlled trial 192 T2DM outpatients were randomized to receive
resveratrol 500 mg/day (Resv500 arm), resveratrol 40 mg/day (Resv40 arm) or placebo for 6 months. BMD, bone
mineral content (BMC), serum calcium, phosphorus, alkaline phosphatase, and 25-hydroxy vitamin D were measured at
baseline and after 6 months.
Results: At follow-up, calcium concentrations increased in all patients, while within-group variations in alkaline
phosphatase were higher in both resveratrol arms, and 25-hydroxy vitamin D increased in the Resv500 arm only,
without between-group differences. Whole-body BMD significantly decreased in the placebo group, while whole-
body BMC decreased in both the placebo and Resv40 arms. No significant changes in BMD and BMC values occurred
in the Resv500 arm. The adjusted mean differences of change from baseline were significantly different in the Resv500
arm vs placebo for whole-body BMD (0.01 vs −0.03 g/cm2, p= 0.001), whole-body BMC (4.04 vs −58.8 g, p < 0.001),
whole-body T-score (0.15 vs −0.26), and serum phosphorus (0.07 vs −0.01 µmol/L, p= 0.002). In subgroup analyses, in
Resv500 treated-patients BMD values increased to higher levels in those with lower calcium and 25-hydroxy vitamin D
values, and in alcohol drinkers.
Conclusions: Supplementation with 500 mg resveratrol prevented bone density loss in patients with T2DM, in
particular, in those with unfavorable conditions at baseline.
Introduction
Type 2 diabetes (T2DM) subjects are at a higher risk for
bone fracture due to altered bone cell function and bone
remodeling, advanced glycation end-product (AGE)
accumulation causing collagen deterioration, and micro-
architectural changes1,2.
The list of the healthy properties of the polyphenolic
compound resveratrol (3,5,4ʹ-trihydroxy-trans-stilbene),
although not all confirmed in human studies3–6, has
recently lengthened after the discovery of the benefits on
bone metabolism for this compound7. Animal studies
have shown that resveratrol prevents bone loss, reduces
mineral density due to immobilization, older age, and
ovariectomy8–11, and causes bone healing and repair after
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surgical procedures or trauma12,13. It promoted osteo-
blastogenesis, antagonized osteoclasts in vitro14–16, and
potentiated vitamin D receptor activity17. However, other
preclinical studies reported mixed or negative effects of
resveratrol on bone health18–21.
Despite this substantial preclinical evidence, human
data about the effects of resveratrol on bone metabolism
are very scarce22,23. An increase in circulating levels of
bone-specific alkaline phosphatase after 4 weeks of
resveratrol supplementation (compared to placebo) has
been described in a small trial in obese men22. Resveratrol
has shown to increase lumbar spine trabecular volumetric
bone mineral density (BMD) in a dose-dependent manner
in middle-aged, obese men with metabolic syndrome23.
We have recently found no metabolic or anti-
inflammatory benefits of resveratrol24, but an increment
in the concentrations of antioxidant markers and
pentraxin-325 in patients with T2DM. In this study
therefore, we have investigated the effects of resveratrol at
dosages of 40 and 500 mg/day for 6 months on BMD and
on the circulating concentrations of calcium metabolism
biomarkers in these patients by a double-blind rando-
mized placebo-controlled trial.
Subjects and methods
Participants
Participants were enrolled at the Diabetic Clinic of the
Department of Medical Sciences of the University of
Turin, between October 2013 and February 2016. Proce-
dures have been previously reported24,25.
Inclusion criteria were: diagnosed T2DM patients,
age ≥ 40 years, body mass index (BMI) < 35 kg/m2,
patients on diet and/or hypoglycemic agents other than
insulin. Exclusion criteria were: treatment with any anti-
oxidant substance, treatment with insulin, anticoagulants,
steroids, or anti-inflammatory drugs different from
aspirin, alcohol or substance abuse, uncompensated dia-
betes, liver or kidney diseases, presence of diabetes-related
chronic complications, cardiovascular events or revascu-
larization procedures in the previous four weeks, or any
severe chronic or life-threatening diseases, pregnancy,
allergy to peanuts, grapes, wine, mulberries.
Study design
The present study was a double-blind, randomized,
placebo-controlled trial, and has been registered in
December 2011 at clinicaltrials.gov (ID NCT01492114).
Intervention
As previously described24, 192 patients were rando-
mized to 1 capsule/day of resveratrol 500 mg/day
(Resv500 arm) for 6 months, 1 capsule/day of resveratrol
40 mg/day (Resv40 arm) for 6 months and 1 capsule/day
of placebo (totally inert microcellulose) for 6 months
(placebo arm) (Supplemental Fig. 1). All participants were
asked to assume one capsule/day in the morning and to
maintain their habitual lifestyle, the diet given by the
Diabetic Clinic, and their current hypoglycemic treatment
during the trial. The use of antioxidant nutritional
supplements or consuming significant amounts of
resveratrol-rich foods and beverages were not allowed
during the trial.
Compliance
Compliance with the study protocol was monitored
with monthly phone calls and pill counting.
All the laboratory measurements were blind and per-
formed at the Laboratory of Metabolic Diseases of the
Department of Medical Sciences, University of Turin.
Outcomes
The primary outcome of the present study was to
measure the difference in changes in BMD values from
baseline to end of trial in patients treated with resveratrol
500mg/day or resveratrol 40 mg/day compared to
patients treated with placebo.
Secondary outcomes were the differences in changes
from baseline to trial end of BMC, serum values of
calcium, phosphorus, alkaline phosphatase (ALP),
25-hydroxy vitamin D in patients treated with resveratrol
500mg/day or resveratrol 40 mg/day compared to
patients treated with placebo.
Randomization
A computer-generated randomization sequence was
developed by a statistician using blocks of various length
in random sequence, and patients were stratified by
use of acetyl-salicylic acid and glycated hemoglobin
(HbA1c) levels (cut-point 7%)24. The procedure was
concealed to researchers and available on a dedicated web
site (www.epiclin.it).
Blinding
The bottles containing resveratrol and placebo capsules
were identical and were prepared by a person who did not
take part in the study and were labeled with patient
identification number. Patients and researchers dispen-
sing the capsules and involved in the trial were blinded to
the bottle content. All laboratory and densitometric ana-
lyses were blind procedures.
Ethical aspects
All procedures were in agreement with the principles of
the Helsinki Declaration; the study protocol was approved
by the Local Ethics Committee. All participants provided
written informed consent to participate in the study.
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Measurements
At baseline and after 6 months (trial end), data related
to health status, the use of drugs or supplements, and
usual dietary habits and exercise levels were collected
from all subjects.
Patients had to complete a validated food-frequency
questionnaire24 and the Minnesota-Leisure-Time-Physi-
cal-Activity questionnaire26.
All the following measurements were collected at
baseline and after 6 months: body weight, waist cir-
cumference, arterial blood pressure, Dual X-ray densito-
metry (DXA) measurements of BMD, bone mineral
content (BMC), and fat percentage. Furthermore, fasting
blood samples were collected to determine the circulating
concentrations of metabolic, and inflammatory variables,
serum calcium, phosphorus, ALP, and 25-hydroxy
vitamin D.
Alcohol intake was assessed by multiplying the mean
daily intake for each beverage by its ethanol content, to
give grams of alcohol/day. Level of physical activity was
calculated as the product of the duration and frequency of
each activity (in hours/week), weighted by an estimate of
the metabolic equivalent (MET) of activity and summed
for activities performed24.
The measurements and the laboratory assays have been
described elsewhere24.
BMD was measured by DXA (QDR-4500; Hologic,
Bedford, MA, USA); areal BMD and BMC at the lumbar
spine (L1-L4), hip, and whole body were measured by
DXA using the same instrument at baseline and at the
trial end. Coefficient of variation of repositioning was
<1.5% for lumbar spine and total hip, and <2% for whole
body.
DXA was used to determine lean and fat body mass,
using whole-body absorptiometry software.
The lumbar, hip, and whole-body BMD T-scores were
calculated according to the following formula: (patient’s
BMD−mean young-adult BMD) / (SD young-adult
BMD).
Blood samples, collected after an overnight fast, were
centrally analyzed.
A direct colorimetric method for determination of
serum calcium and phosphorus was used (Sentinel,
Milan) with intra-assay and inter-assay variation coeffi-
cients (CVs) of 0.4–0.9 and 1.5–1.7% (calcium) and
0.7–1.2 and 2.2–4.4% (phosphorus), respectively. An
enzymatic colorimetric method was used for determina-
tion of serum ALP (Sentinel, Milan) according to the
DGKC recommendations with an intra-assay and inter-
assay CVs of 0.8–2.1 and 1.6–1.9%. 25-hydroxy vitamin D
was determined by competitive solid phase enzyme
linked immunosorbent assay (Global Diagnostic B, Bel-
gium). The kit has a sensitivity of 2.6 ng/ml in a 25-µL
sample size and a range of 0 to 105 ng/ml. The intra-assay
and inter-assay CVs were, respectively, 3.6–8.6 and
6.4–7.7%.
Statistical methods
The sample size was originally calculated for another
outcome, the reduction of C-reactive protein (CRP):
to obtain an effect size of 0.5027, a total sample size of
192 patients (about 64 per arm) was necessary to reach a
statistical power of 80% considering an overall type 1 error
of 5%24.
Within-group comparisons were analyzed by t-test for
paired samples or Wilcoxon-matched paired test, as
appropriate.
Analysis of covariance (ANCOVA) was used to compare
changes from baseline of the analyzed endpoints between
the resveratrol and placebo arms, adjusted for the baseline
endpoint measurement, stratification variables used in the
randomization (aspirin use and HbA1c concentrations),
gender, and use of calcium/vitamin D supplements. For
each endpoint, a global test was performed to evaluate if
at least one of two resveratrol arms showed significantly
different changes with respect to the placebo arm.
To preserve the overall 5% type 1 error, a gatekeeping
strategy was adopted accounting for the hierarchical
structure of multiple comparisons in the first step. The
Resv500 arm was first compared with placebo and only if
this test was statistically significant at p < 0.05, a
comparison between Resv40 arm and placebo with a test
p < 0.05 was considered as significant.
Exploratory subgroup analyses were performed to
identify potential interactions with the experimental
treatment according to patient characteristics (age,
gender, exercise levels expressed by METs, baseline per-
cent body fat mass, baseline calcium, or 25-hydroxy
vitamin D levels), disease conditions (diabetes duration,
HbA1c values), and other variables (aspirin or statin use,
smoking, alcohol consumption, and hypoglycemic drugs).
Subgroup analyses were adjusted for the all same variables
used for adjusting the ANCOVA analyses (aspirin use,
HbA1c, gender, use of calcium/vitamin D supplements).
Statistical analyses were performed using Stata
13.2 software (StataCorp LP, College Station, Texas).
Results
Median age of the enrolled patients was 66 years
(interquartile range 60–70); 66% were males; all females
were in menopause. Mean BMI and percent body fat
were, respectively, 28.8 ± 3.9 kg/m2 and 32.3 ± 7.6%; these
values as well as dietary intakes and exercise levels were
similar among the three arms24.
Out of the 192 patients, 65 were randomized to the
Resv500 arm, 65 to the Resv40 arm, and 62 to the Placebo
arm. At the trial end, 3, 6, and 4 patients, respectively,
dropped out and data of 62, 59, and 58 patients from
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Resv500, Resv40, and Placebo arms were available
(Supplemental Fig. 1).
More than 95% compliance was detected through pill
counting; no serious adverse event occurred.
Calcium/vitamin D supplements were taken by 2/3/3
patients, respectively, in the Resv500, Resv40 and Placebo
arms, whereas the corresponding proportions of indivi-
duals treated with metformin, sulfonylureas, and incretin
drugs were respectively 67.7, 35.4, 26.2% (Resv500), 67.7,
32.3, 29.2% (Resv40), and 66.1, 37.1, 24.2% (Placebo).
No participant was treated with thiazolidinediones or
gliflozins.
Baseline variables were homogenous for placebo and the
resveratrol arms (Table 1), however, the proportion of
female participants in the Resv40 group was higher and
was a casual occurrence, as no gender stratification had
been planned.
Overall, the resveratrol arms showed significantly dif-
ferent changes in serum phosphorus, whole-body BMD
and whole-body BMC with respect to the placebo arm. In
detail, the adjusted mean differences of change from
baseline significantly differed only in the Resv500 arm
versus Placebo: phosphorus (0.07 vs −0.01 µmol/L,
respectively, Resv500 and Placebo groups), whole-body
BMD (0.01 vs −0.03 g/cm2), whole-body BMC (4.04 vs
−58.8 g), whole-body T-score (0.15 vs −0.26) (Table 2).
In all the three arms, calcium concentrations increased
after 6-month follow-up, but mean changes were not
significantly different between groups. Within-group
changes in ALP were higher in both resveratrol arms,
and 25-hydroxy vitamin D and whole-body T-score in the
Resv500 group, only. Whole-body BMD and whole-body
T-score significantly decreased within the Placebo group,
while whole-body BMC values were reduced within
both the Placebo and the Resv40 arms. No significant
changes in BMD and BMC values were observed in the
Resv500 arm.
Data did not meaningfully change after excluding the
8 patients on calcium/vitamin D supplements, and after
adjusting for duration of diabetes and HbA1c values.
Subgroup analyses were performed to analyze potential
factors which could have modified the effects of resvera-
trol administration (Figs. 1 and 2). There was no hetero-
geneity of effects for the evaluated variables in the
Table 1 Baseline variables by arm of the trial
Placebo arm Resv40 arm Resv500 arm P*
Number 62 65 65
Age (years) 65.4 ± 8.8 64.9 ± 8.6 65.0 ± 7.6 0.94
Males (%) 75.8 58.5 63.1 0.10**
Diabetes duration (years) 8.0 (10.0) 7.0 (13.0) 7.0 (10.0) 0.98***
Glycated hemoglobin (%) 6.9 ± 1.0 7.2 ± 1.3 6.9 ± 1.2 0.33
Calcium (mmol/L) 2.07 ± 0.25 2.03 ± 0.24 2.00 ± 0.18 0.30
Phosphorus (mmol/L) 1.23 ± 0.22 1.27 ± 0.24 1.33 ± 0.26 0.06
Alkaline phosphatase (U/L) 146.4 ± 38.1 157.6 ± 45.5 142.5 ± 38.6 0.09
25 hydroxy vitamin D (ng/mL) 20.1 ± 10.5 21.6 ± 11.1 19.6 ± 8.0 0.49
BMD (g/cm2)
Lumbar spine 1.03 ± 0.19 0.98 ± 0.16 0.96 ± 0.18 0.12
Total hip 0.97 ± 0.15 0.97 ± 0.12 0.95 ± 0.16 0.88
Whole body 1.08 ± 0.14 1.06 ± 0.12 1.06 ± 0.13 0.66
BMC (g)
Lumbar spine 57.7 ± 15.2 53.0 ± 18.6 52.8 ± 16.5 0.18
Total hip 41.0 ± 10.7 38.9 ± 8.8 38.7 ± 11.0 0.39
Whole body 2326.5 ± 509.0 2205.5 ± 461.5 2204.4 ± 520.0 0.29
T-score
Lumbar spine −0.6 (2.1) −1.0 (1.6) −1.0 (2.1) 0.31***
Total hip −0.4 (1.6) −0.3 (1.0) −0.4 (1.3) 0.65***
Whole body −1.1 (1.3) −1.5 (1.5) −1.2 (1.8) 0.60***
*p-values obtained by ANOVA; **p-values obtained by chi-square test; ***p-values obtained by Kruskal–Wallis test
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adjusted mean difference on changes from baseline of
BMD values in the Resv40 arm vs the Placebo arm,
except in the case of patients treated with sulfonylur-
eas (Fig. 2). BMD values increased in almost all sub-
groups of the Resv500 arm when compared to the
Placebo arm (Fig. 1). A statistically significant inter-
action for BMD was noted relatively to alcohol intake,
baseline calcium and 25-hydroxy vitamin D con-
centrations, since BMD values increased more in
patients with alcohol intake, and in those with lower
than median values of calcium and 25-hydroxy
vitamin D (Fig. 1).
Discussion
Resveratrol supplementation was associated with
positive effects on bone density in patients with
T2DM, and particularly in those with unfavorable
conditions at baseline.
Animal and in vitro studies have shown a protec-
tive effect of resveratrol on bone status by the pre-
vention of bone mass reduction and downregulation
of bone turnover thus preserving bone structure,
volume, microarchitecture, and mechanical strength;
it also enhances bone formation and growth, by
antagonizing osteoclasts, promoting osteogenic dif-
ferentiation and osteoblast activity, and decreasing
the bone marrow mesenchymal stem cell differ-
entiation into adipocytes, mediated by the activation
of Sirtuin-1 (SIRT-1)8–13,15,28,29.
The presumed mechanism by which resveratrol may
exert its beneficial effects on the bone are: increased
bone sulfhydryl content and reduction in bone pro-
inflammatory mediators (malondialdehyde, IL-6,
TNFα, etc), VEGF, and oxidative stress (which is
involved in the development of osteoporosis), the
hypothesized estrogenic activity, suppression of
the upregulation of mRNA levels of Peroxisome
proliferator-activated receptor-γ (PPARγ), restoration
of bone mRNA levels of insulin-like growth factor 1
(IGF-1) and Wnt/β-catenin signaling pathway, upre-
gulation of the expression of osteo-lineage genes
RUNX2, and upregulation of the gene expression of
bone morphogenetic proteins8–13,30,31. Furthermore,
the suppression of the release of bone pro-
inflammatory cytokines by resveratrol may reduce
receptor activator for NF-κB ligand (RANKL) expres-
sion by osteoblasts, thus inhibiting osteoclast pro-
liferation and bone resorption11.
Not all studies were consistent, as neutral or nega-
tive bone effects of resveratrol have also been descri-
bed18–21,32. Possible explanations of these divergences
may be because of the different duration of supple-
mentation, different models, species, or experimental
conditions, and the type of supplement employed.Ta
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Furthermore, the effectiveness of resveratrol is quite
different when tested in in vitro or animal studies when
compared to clinical trials in humans4.
Chronic sub-clinical inflammation and oxidative stress
associated with diabetes might contribute to the unheal-
thy bone status of T2DM patients, together with other
mechanisms, such as the increased skeletal content of
advance glycation end products (AGEs), the altered dif-
ferentiation of osteogenic cells, the altered bone turnover
and microarchitecture1,2. Bone loss due to inflammation
is associated with greater resorption activity by osteo-
clasts8. In our patients, the maintenance of BMD and the
increase in ALP suggested that resveratrol might attenu-
ate diminished bone formation found in T2DM patients
on placebo. However, we have recently failed to detect any
anti-inflammatory effects of resveratrol in the patients
under study24. Indeed, recent animal studies showed that
resveratrol has a beneficial role on osteoblasts indepen-
dently of inflammation, thus being a more general bone
protective agent14. The two currently available human
studies were in line with our results. The first short-term
(4 weeks) trial, performed in 24 obese non-diabetic men,
12 randomized to a high-dose (1500mg/day) resveratrol
supplementation, and 12 to placebo, found a 15% increase
in bone-specific ALP and a trend in total ALP increment,
not reaching statistical significance, while inflammatory
markers did not change22. In the other clinical trial, men
with metabolic syndrome were randomized for 16 weeks
to 150 mg/day resveratrol (n= 21), 1000 mg/day resvera-
trol (n= 21), or placebo (n= 24), and a dose-dependent
increase in bone ALP and in lumbar spine volumetric
BMD were found, with no changes in inflammatory
markers23.
In the latter study, lumbar spine bone mass and density
increased in a dose-dependent manner in the resveratrol-
treated men, while no consistent change at total hip and
whole body was detected23. We have shown that the
supplementation with 500mg resveratrol prevents the
reduction of BMD and BMC observed in patients treated
with placebo. However, the inclusion in our sample of
older T2DM individuals and menopausal women might
justify these differences.
Three further considerations should be made: firstly, in
a 6-month period, our non-supplemented T2DM patients
Statins
Sulfonylureas
HbA1c
Incretins
Aspirin use
Metformin
METS (h/week)
Alcohol
Age
Current Smoker
Baseline Calcium (mmol/L)
Basel. 25-hydroxy vitamin D (ng/mL)
Strata
Gender
Disease Duration
Fat mass (%)
Overall
No (N=52)
Yes (N=30)
>=7% (N=50)
No (N=78)
<7% (N=70)
No (N=90)
Yes (N=42)
No (N=78)
Yes (N=70)
Yes (N=23)
>=20 (N=52)
No (N=40)
>=30 (N=63)
<30 (N=59)
>=30 (N=61)
No (N=50)
>=2.0 (N=64)
<65y (N=49)
>=65y (N=71)
No (N=97)
Males (N=36)
<2.0 (N=56)
<20 (N=68)
Yes (N=68)
Subgroup
Yes (N=80)
Females (N=84)
Yes (N=42)
<8y (N=59)
<30 (N=57)
>=8y (N=61)
0.03 (0.03, 0.04)
0.03 (0.01, 0.05)
0.05 (0.02, 0.08)
0.03 (0.01, 0.06)
0.03 (0.02, 0.05)
0.03 (0.01, 0.05)
0.03 (0.01, 0.04)
0.03 (0.01, 0.05)
0.03 (0.02, 0.05)
0.04 (0.03, 0.06)
0.03 (-0.01, 0.06)
0.01 (-0.01, 0.04)
0.02 (0.00, 0.05)
0.04 (0.02, 0.06)
0.04 (0.02, 0.06)
0.02 (0.00, 0.04)
0.01 (-0.01, 0.04)
0.02 (-0.00, 0.04)
0.02 (0.00, 0.04)
0.04 (0.02, 0.05)
0.03 (0.02, 0.05)
0.04 (0.01, 0.07)
0.05 (0.03, 0.07)
0.05 (0.03, 0.06)
0.03 (0.01, 0.05)
Difference (95% CI)
0.03 (0.02, 0.05)
0.03 (0.01, 0.05)
0.03 (0.00, 0.05)
0.02 (0.00, 0.04)
0.03 (0.01, 0.05)
0.04 (0.02, 0.06)
0.03 (0.02, 0.05)
Adjusted Mean
.85
.75
.8
.17
.88
.5
.36
.036
.32
.75
.02
.033
Interaction
.48
.15
.38
0
0
0
0-.0768 .0768
*Dashed lines indicate the Overall Effect 
Fig. 1 Adjusted mean difference on change from baseline (95% CI) of total BMD values (Resv500 arm vs Placebo arm)
Bo et al. Nutrition and Diabetes  (2018) 8:51 Page 7 of 10
Nutrition and Diabetes
showed a ~3% bone mass loss. Therefore, even if BMD
values are reported to be increased in T2DM patients
when compared to controls1,2, also in the diabetic patients
within our age range a significant bone loss was evident in
a relatively short period of time. Secondly, although the
effect of 500mg resveratrol on bone density was low, a
~1% increase over a 6-month intervention period, seems
to be relevant, especially considering bone loss incurring
in controls, and therefore worth to be tested in long-term
trials. Finally, we found benefits on whole-body BMD,
BMC, and T-scores, but not on lumbar spine or total hip
values, which are the clinically useful measures to predict
the risk of osteoporotic fractures. Indeed, in overweight/
obese individuals, as are our participants and most T2DM
patients, the greatest risk seems to be that of appendicular
fractures33,34. Therefore, the beneficial effects on whole-
body measures may be clinically relevant in these subjects.
Although ALP is a non-specific isoenzyme, it is con-
sidered as an acceptable marker for bone forma-
tion11,14,22,23,28. ALP acts as a transmembrane receptor
involved in osteoprogenitor–osteoblast adhesion, migra-
tion, and differentiation, whereas mineralization is caused
by coprecipitation of calcium and inorganic phosphates
(generated by ALP catalyzed glycerophosphate degrada-
tion) onto a collagen matrix35. We have found a
significant within-group increase in ALP values in the
resveratrol arms, thought the differences were not
significantly different from placebo.
Resveratrol shares some similar mechanisms with vita-
min D, one of the regulators of calcium and phosphorus
homeostasis, and these two substances show important
mutual processes and interactions36. In particular,
vitamin D, besides modulating a variety of pathways such
as cell growth and division, regulation of immune
responses and antimicrobial defense, xenobiotic detox-
ification, carcinogenesis, neuroprotection, and insulin
regulation, has shown, similarly to resveratrol, to inhibit
adipogenesis and stimulate osteoblastogenesis, partly
because of its ability to inhibit PPARγ expression29.
Resveratrol potentiates 1,25-dihydroxyvitamin D3-
binding to the Vitamin D receptor (VDR), activates its
co-receptor, the Retinoid X Receptor (RXR), and stimu-
lates SIRT-1, an enzyme able to potentiate vitamin D
signaling via VDR deacetylation37,38.
Strata
Fat mass (%)
Baseline Calcium (mmol/L)
Metformin
Aspirin use
HbA1c
Basel. 25-hydroxy vitamin D (ng/mL)
Incretins
Alcohol
Sulfonylureas
Gender
Age
Disease Duration
Statins
Current Smoker
Overall
METS (h/week)
Subgroup
<30 (N=48)
Yes (N=69)
<2.0 (N=52)
>=20 (N=57)
Males (N=34)
Yes (N=39)
No (N=40)
>=30 (N=69)
No (N=77)
<7% (N=67)
Yes (N=77)
>=30 (N=56)
<20 (N=60)
Yes (N=30)
>=2.0 (N=65)
No (N=87)
>=7% (N=50)
>=65y (N=69)
Yes (N=23)
No (N=48)
Yes (N=62)
No (N=78)
Females (N=83)
<65y (N=48)
>=8y (N=59)
<8y (N=58)
No (N=55)
Yes (N=40)
No (N=94)
<30 (N=61)
0.02 (0.01, 0.02)
Difference (95% CI)
0.02 (-0.01, 0.06)
0.00 (-0.03, 0.03)
0.02 (-0.01, 0.05)
0.02 (-0.01, 0.05)
0.02 (-0.02, 0.06)
-0.01 (-0.05, 0.02)
0.03 (-0.01, 0.07)
0.01 (-0.01, 0.04)
0.02 (-0.01, 0.05)
0.02 (-0.01, 0.05)
0.01 (-0.02, 0.04)
0.02 (-0.01, 0.05)
0.01 (-0.02, 0.04)
Adjusted Mean
0.05 (0.00, 0.09)
0.02 (-0.01, 0.05)
0.01 (-0.02, 0.03)
0.01 (-0.02, 0.05)
0.01 (-0.02, 0.04)
0.00 (-0.05, 0.05)
0.03 (0.00, 0.07)
0.00 (-0.03, 0.03)
0.03 (0.01, 0.06)
0.02 (-0.01, 0.04)
0.02 (-0.01, 0.05)
0.02 (-0.01, 0.06)
0.01 (-0.02, 0.04)
0.03 (0.00, 0.07)
0.01 (-0.03, 0.05)
0.02 (-0.00, 0.05)
0.02 (-0.00, 0.04)
0.01 (-0.02, 0.04)
Interaction
.66
.93
.45
.64
.63
.76
.15
.14
.047
.86
.75
.63
.14
.54
.60
0-.0893 .0893
*Dashed lines indicate the Overall Effect. 
Fig. 2 Adjusted mean difference on change from baseline (95% CI) of total BMD values (Resv40 arm vs Placebo arm)
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Accordingly, we found a slightly significant increase in
25-hydroxy vitamin D circulating levels in patients treated
with 500 mg resveratrol. Moreover, calcium and phos-
phorus concentrations increased after resveratrol treat-
ment, even if only the changes in phosphorus levels were
significantly different in the Resv500 arm. Similarly,
higher femoral phosphorous, but not calcium, was found
in hindlimb-suspended rats given resveratrol8, and plasma
calcium levels were unchanged after resveratrol supple-
mentation in humans22,23. A different regulation of cal-
cium and phosphorus absorption by vitamin D has been
called into question: vitamin D enhances the absorption of
phosphorus by increasing the activity of ALP brush bor-
der, which hydrolyzes phosphorus ester bonds8. Indeed,
the beneficial effect of resveratrol on bone was reported to
be vitamin D-independent13, and the expression pattern
for osteoblast markers was different for these two sub-
stances29. Therefore, a specific effect of resveratrol on
phosphorus metabolism could not be excluded.
The dose-effect of resveratrol was a confirmation of the
causal-effect relationship between resveratrol supple-
mentation and bone health, since the beneficial effects on
all outcomes were enhanced with increasing doses of the
supplement. If confirmed by further studies, the potential
anabolic osteogenic properties of resveratrol might be
particularly interesting for older T2DM patients, char-
acterized by gradual bone loss due to reducing osteoblast-
mediated bone formation7.
Subgroup analyses
Resveratrol seemed to be more effective on BMD in
subgroups with unfavorable baseline characteristics, i.e.,
those with lower baseline values of calcium/25 hydroxy
vitamin D, and alcohol drinkers. This is intriguing, since
all these conditions give to a higher risk of bone demi-
neralization, microstructural deterioration, and fractures.
Alcohol increases the risk for loss of BMD and impair-
ment of bone remodeling, by an inhibitory effect on
osteogenic differentiation of bone marrow-derived
mesenchymal stem cells (BM-MSCs), inducing a pre-
mature senescence-associated phenotype in these cells,
also at moderate doses39. We have excluded heavy alcohol
drinkers from the present trial, but <30 g/day alcohol
consumers have been enrolled. We found an increased
benefit of resveratrol 500 mg on BMD values in alcohol
consumers. Indeed, resveratrol supplementation via
SIRT-1 activation was shown to be able to suppress
senescence phenotypes in BM-MSCs, partially counter-
acting the effects of ethanol and rescuing the inhibited
osteogenesis39.
Finally, patients in the Resv40 arm and not on sulfo-
nylureas showed an increase in BMD. A neutral effect of
sulfonylureas on the risk of fractures in T2DM patients
was reported by a few observational studies, suffering
from many limitations40. However, sulfonylureas can
cause hypoglycemia, leading to an increased risk of falls
and therefore to fractures, as recently demonstrated in a
large cohort study41. Data about the incidence of hypo-
glycemia in our patients were not available, and thus we
were not able to test this hypothesis.
Limitations
This trial has a few limitations, such as the unfeasibility
of DXA for evaluation of changes in bone geometry and
microstructure; the precision error of DXA measure-
ments increases with higher BMI; biochemical markers of
bone turnover and serum parathormone levels were not
measured; the determination of circulating variables does
not necessarily reflect actions at the tissue level; even if
our study had the longest time duration among published
human trials, it could not determine the impact of
resveratrol on the fracture risk, the major bone compli-
cation of T2DM patients. Furthermore, the sample size
was originally calculated on CRP value reduction24;
indeed, we estimated “a posteriori” that the present study
achieved a power= 80% to detect a difference of 0.019 in
BMD change from baseline between the Resv500 and the
Placebo arms, with a two-tailed α-value= 0.05. Finally,
the subgroup analyses were based on small groups and did
not allow to obtain definitive conclusions.
However, our results were consistent, and in accordance
with the existing literature. Moreover, this is the first trial
evaluating the bone effects of resveratrol in T2DM
patients. Other strengths included its randomized
placebo-controlled double-blind design; the high patients’
adherence, and the centralized measurements.
Conclusion
In conclusion, the supplementation with resveratrol was
associated with slight beneficial effects on bone density in
patients with T2DM, especially in specific high-risk sub-
groups of patients. Additional studies are required to
demonstrate whether the continuous administration of
resveratrol could reverse the increased risk of bone frac-
tures of these patients.
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